Impact of the Indoleamine 2,3-dioxygenase (IDO) system and its metabolites on molecular response to Nilotinib therapy in early Chronic Phase Chronic Myelogenous Leukemia (CML-CP)

S. Sopper, S. Mustjoki, G. Gastl, Z. Trajanoski, F. Giles, A. Hochhaus, J. Janssen, S. Geissler, D. Fuchs, D. Wolf

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)220-220
JournalONCOLOGY RESEARCH AND TREATMENT
Volume39
Publication statusPublished - Oct 2016

Cite this